Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carrie Dylla

Nurse Practitioner, Psychiatric/Mental Health Watertown, SD Physician Assistant

NPI 1245274240 CMS profile 10429554

123 19Th Street Ne, Watertown, SD 57201

Open in the dashboard

General payments

$4,320

311 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carrie Dylla of Watertown, SD is reported in the CMS Open Payments database as having received $4,320 across 311 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,516 109
2024 General $1,008 70
2023 General $699 57
2022 General $674 48
2021 General $423 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carrie Dylla
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Carrie Dylla were reported at $1,516. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Carrie Dylla Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $423 $166 $54–$482 $132
2022 $674 $195 $66–$559 $149
2023 $699 $233 $82–$673 $160
2024 $1,008 $236 $84–$688 $164
2025 $1,516 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,043 118 payments
  2. Alkermes, Inc. $532 27 payments
  3. Neurocrine Biosciences, Inc. $342 26 payments
  4. Janssen Pharmaceuticals, Inc $340 20 payments
  5. Otsuka America Pharmaceutical, Inc. $339 19 payments
  6. ITI, Inc. $306 17 payments
  7. Teva Pharmaceuticals USA, Inc. $272 20 payments
  8. Vanda Pharmaceuticals Inc. $176 8 payments
  9. Sunovion Pharmaceuticals Inc. $175 13 payments
  10. Axsome Therapeutics, Inc. $142 7 payments
  11. Other $653 36 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,273 310 payments
  2. Education $47 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $754 83 payments
  2. LYBALVI $441 22 payments
  3. ARISTADA Cns $415 21 payments
  4. ARISTADA Cns $415 21 payments
  5. ARISTADA Cns $337 17 payments
  6. ARISTADA Cns $337 17 payments
  7. INGREZZA $315 24 payments
  8. VRAYLAR Neuroscience $289 35 payments
  9. INVEGA SUSTENNA $285 17 payments
  10. CAPLYTA $231 13 payments
  11. Other $2,699 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

5,363

Median for Physician Assistant: 241

Drug cost

$1,277,620

Median for Physician Assistant: $4,110

Branded share of claims

21.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aristada Aripiprazole Lauroxil Brand 100 $350,402
Invega Sustenna Paliperidone Palmitate Brand 72 $227,446
Ingrezza Valbenazine Tosylate Brand 14 $106,762
Vraylar Cariprazine Hcl Brand 82 $105,858
Invega Trinza Paliperidone Palmitate Brand 11 $104,974
Uzedy Risperidone Brand 16 $64,534
Lybalvi Olanzapine/Samidorphan Malate Brand 34 $51,710
Fanapt Iloperidone Brand 11 $38,879
Rexulti Brexpiprazole Brand 17 $25,058
Auvelity Dextromethorphan Hbr/Bupropion Brand 20 $21,993

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$18,368

Medicare's payments for the services billed

Medicare patients

120

Average age 58

Services billed

296

70 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 58%
High blood pressure 52%
Arthritis 29%
Diabetes 28%
Chronic kidney disease 16%
COPD 14%
Ischemic heart disease 13%
Atrial fibrillation 9%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $225
$225 82 —
ARISTADA
  • Alkermes, Inc. $113
$113 100 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $42
  • Lundbeck LLC $36
$79 17 —
INGREZZA
  • Neurocrine Biosciences, Inc. $77
$77 14 —
CAPLYTA
  • ITI, Inc. $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

311 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record